NanoDoce made available for urogenital cancer patients outside trials
NCT ID NCT04060628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program offers expanded access to NanoDoce for patients with urogenital cancers who cannot join ongoing clinical trials. The goal is to provide the treatment to those in need. No specific eligibility details are listed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROGENITAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Could a targeted drug delay prostate cancer progression?
- Skin-Saving paste for cancer radiation falls short in tiny trial
- New scan spots prostate cancers standard MRI misses
- New test may predict immunotherapy success in bladder cancer
- New PET scan agent could spot kidney cancer more accurately